The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to progress, with more than 103 million global cases and more than 2.2 million deaths as of February 2, 2021.
1 While the world awaits the distribution of effective vaccines, a number of pharmacologic agents have been studied for treatment of coronavirus disease 2019 (COVID-19), the syndrome caused by SARS-CoV-2. Remdesivir, a nucleotide analogue prodrug with in vitro effects against a broad array of RNA viruses,
2-4 has received considerable attention.
3,5,6 Clinical trials assessing the effectiveness of remdesivir have yielded conflicting results
7-12; have not included a sufficient number of patients from groups most affected by COVID-19, such as Black or Latinx individuals
13; and have not examined the coadministration of remdesivir with other drugs. The US Food and Drug Administration (FDA) approved the use of remdesivir for the treatment of hospitalized patients with COVID-19
14 based mostly on the results of the Adaptive COVID-19 Treatment Trial (ACTT-1),
11 whereas the World Health Organization (WHO) recommended against the use of remdesivir
15 based on results from the Solidarity trial.
12